Skip to main content

Table 3 Summary of secondary endpoints during part II among inadequate responders from part I

From: Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial

  Etoricoxib 60 mg (Part I)/60 mg (Part II) Etoricoxib 60 mg (Part I)/90 mg (Part II) LS Mean Difference Between Etoricoxib 60 mg/90 mg vs. Etoricoxib 60 mg/60 mg; p-valuea
LS Mean Change from Week 6 in PGAP over Weeks 10 and 12 −11.96 (−14.96, −8.97) −10.35 (−13.32, −7.39) 1.61 (−0.49, 3.71); p = 0.327
LS Mean Change from Week 6 in PGART over Weeks 10 and 12 0.33 (0.19, 0.46) 0.24 (0.10, 0.37) −0.09 (−0.18, 0.00); p = 0.215
LS Mean Change from Week 6 in DAS28-CRP over Weeks 10 and 12 −0.35 (−0.51, −0.18) −0.39 (−0.55, −0.23) −0.05 (−0.22, 0.13); p = 0.611
  1. ap-values for secondary endpoints were not adjusted for multiplicity and are therefore nominal; statistical significance cannot be inferred from p-values for these endpoints